Recipharm AB: Invitation to Presentation of Recipharm’s Interim Report for the First Quarter of 2014 on May 8

Regulatory News:

Recipharm (STO:RECI) will publish its interim report for January-March 2014 on May 8 at 07:45 CET. The company invites investors, analysts and media to a conference call with a web presentation (in English) on May 8 at 10:00 CET, where CEO Thomas Eldered and CFO Björn Westberg will present and comment on the interim report and answer questions.

The report will be available on Recipharm’s website www.recipharm.com from 07:45 CET the same day.

To participate in the teleconference, please dial:

From Sweden, tel: +46 8-506 443 86

From the UK, tel: +44 20 7153 9154

From Denmark, tel: +45 32 71 42 62 F

rom Finland, tel: +358 9 8171 0375

Pin code for participants: 610969#

To access the presentation during the conference, please use the following link: http://event.onlineseminarsolutions.com/r.htm?e=790519&s=1&k=14C38F170510E2C72A5078973AF57A6C

To access the presentation afterwards, please use the following link: http://event.onlineseminarsolutions.com/r.htm?e=790519&s=1&k=14C38F170510E2C72A5078973AF57A6C

For questions about participation at the event, please contact:

Linda Holmström, Brand & Communications Manager Tel: +46 70 873 40 95; e-mail: linda.holmstrom@recipharm.com

About Recipharm

Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry based in Sweden employing some 1,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and pharmaceutical product development. Recipharm currently manufactures more than 200 different products to both Big Pharma and smaller research- and development companies. Recipharm’s turnover is approximately SEK 2.1 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered in Jordbro.

This information was brought to you by Cision http://news.cision.com